A person qualifies for a gabapentin dementia lawsuit claim if they took six or more gabapentin prescriptions and later received a documented diagnosis of dementia, mild cognitive impairment, or significant memory loss, according to criteria used by plaintiff law firms. These firms describe a formal medical diagnosis as the threshold — not temporary dizziness, confusion, or brain fog while on the drug, according to Robert King Law Firm. Gabapentin is a nerve-pain and anti-seizure medication sold under brand names including Neurontin. The current wave of claims centers on a 2025 study linking extended use to higher rates of dementia diagnosis, and eligibility right now is defined by individual law firms rather than by any court or government ruling.
Official resources:
- Read the official notice from Drugwatch — Use this primary source to verify the official announcement.
- Read the official notice from Lawfold — Use this primary source to verify the official announcement.
Table of Contents
- What the Study Behind These Claims Found
- The Specific Criteria Firms Use to Screen Claims
- Why There's No Class Action or Settlement to Join Yet
- How This Differs From the Earlier Neurontin Litigation
- What the Science Doesn't Yet Establish
- Frequently Asked Questions
What the Study Behind These Claims Found
A 2025 retrospective cohort study in *Regional Anesthesia & Pain Medicine*, led by Nafis Eghrari and colleagues at Case Western Reserve University, analyzed 26,416 chronic-pain patients across 68 U.S. health systems using the TriNetX research network, according to BMJ Group. The study compared patients prescribed gabapentin against matched patients who were never prescribed it. Patients with six or more gabapentin prescriptions showed a 29% higher rate of dementia diagnosis and an 85% higher rate of mild cognitive impairment diagnosis within 10 years, compared with the matched group, according to BMJ Group.
The risk tracked with how much gabapentin a patient took: those with 12 or more prescriptions had a higher incidence than those with 3 to 11, according to Science Media Centre. Age mattered too. Adults aged 18 to 64 — with the strongest association in the 35-to-49 group — showed more than double the risk compared with people who never took the drug, according to Science Media Centre. That age pattern is part of why early-onset diagnosis, rather than diagnosis in old age, has become central to how firms screen potential claims.
The Specific Criteria Firms Use to Screen Claims
At least one firm, Robert King Law Firm, has published concrete intake rules built directly on the study's findings. Its stated criteria require six or more gabapentin prescriptions filled between 2000 and 2024, use of the drug for a condition other than seizures or nerve pain — gabapentin's FDA-approved indications — and a dementia diagnosis before age 65, according to Robert King Law Firm. These are one firm's own screening rules, not a uniform legal standard that every attorney or court applies.
A different firm could set its own thresholds for prescription count, diagnosis age, or qualifying condition. Anyone considering a claim should ask a prospective attorney directly what their specific intake criteria require, since a profile that doesn't meet one firm's bar may still meet another's. The off-label use condition is notable: gabapentin is approved for seizures and nerve pain, so a person who took it for an approved use may not fit this screening profile, even with a later dementia diagnosis. The emphasis on off-label prescribing echoes long-running scrutiny of gabapentin's marketing history, which is addressed in Section 4.
Why There's No Class Action or Settlement to Join Yet
As of September and October 2026, no federal multidistrict litigation (MDL) has been established for gabapentin dementia claims. Cases are being filed individually in state courts rather than consolidated into one proceeding or certified as a class action, according to Drugwatch and Lawfold. No jury trials have occurred and no settlements have been publicly announced for these dementia-related claims, according to Lawfold.
Because there is no MDL and no settlement fund, there is also no government website, claims administrator, or public enrollment form to sign up through. A person who believes they qualify has to retain a private attorney and file an individual claim, according to Drugwatch. Every state sets its own statute of limitations — a deadline for filing a civil claim — so the window to act narrows the longer a diagnosed person waits, according to Drugwatch.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
- No class action has been certified
- No MDL has consolidated the cases
- No settlement exists to apply to
- Filing happens through a private attorney, case by case
How This Differs From the Earlier Neurontin Litigation
Gabapentin has been the subject of litigation before, but under different facts. The Neurontin marketing-fraud MDL (No. 1629, D. Mass., Civil Action No.
04-10981-PBS) was a federal case concerning the drug's off-label promotion, not dementia risk, according to Lawfold. That case is closed. The current dementia-related claims are a separate, newer wave triggered by the 2025 cohort study, and they have not reached the scale of consolidation that the earlier Neurontin litigation did. Anyone researching "gabapentin lawsuit" online should check which wave a given source is describing, since the legal posture, evidence, and eligibility rules are not interchangeable between the two.
What the Science Doesn't Yet Establish
The study's own authors acknowledged a limitation: the data could not account for the actual dose or duration of gabapentin use, only the number of prescriptions filled, according to Science Media Centre. Outside experts raised two alternative explanations for the association. One is confounding: chronic pain itself often reduces physical activity, and inactivity is separately linked to higher dementia risk.
The other is reverse causality: undiagnosed early cognitive decline may be what prompts a gabapentin prescription in the first place, rather than the drug causing the decline, according to Science Media Centre. That means eligibility for a claim right now turns on firm-specific intake criteria built around this association study, not on any regulatory finding or court ruling that gabapentin causes dementia, according to Science Media Centre. The underlying science remains an unproven association, and that distinction matters for anyone deciding whether to pursue a claim and for understanding what a case would need to prove.
- A documented diagnosis of dementia, MCI, or significant memory loss is required — not symptoms alone
- A prescription history of six or more fills is the threshold at least one firm uses
- Off-label use (not for seizures or nerve pain) and early-onset diagnosis (before 65) are part of that firm's specific profile
- No class action, MDL, or settlement exists to join — claims are filed individually
- State statutes of limitations set a filing deadline that varies by jurisdiction
Frequently Asked Questions
Can I join a gabapentin dementia class action lawsuit?
No class action has been certified for these claims. Cases are being filed individually in state courts, according to Drugwatch.
Does taking gabapentin for nerve pain or seizures qualify someone for a claim?
Under at least one firm's published criteria, use for seizures or nerve pain — gabapentin's approved indications — does not fit the screening profile; the criteria target off-label use, according to Robert King Law Firm.
Is there a settlement fund to apply to right now?
No. No settlement has been publicly announced, and no MDL has consolidated the cases, according to Lawfold.
You Might Also Like
- Gabapentin Dementia Lawsuit Eligibility Criteria
- Spinal Cord Stimulator Lawsuit Update: Who Qualifies for a Claim?
- Depo-Provera Lawsuit Payouts for Brain Tumor Claims